FDA approves Zydus Lifesciences’ ZITUVIO tablets for Type 2 diabetes
Zydus Lifesciences Limited announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets in three dosages: 25 mg, 50 mg, and 100 mg. What is ZITUVIO? Containing the active ingredient Sitagliptin, ZITUVIO functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It’s specifically designed […]